I think I was pretty clear but essentially a heavily resourced Big Pharma expecting a pre-revenue biotech to do a combination trial on speculation and for said company to provide pretty much nothing except their own product would be a ‘fake partnership.’
Such an arrangement would not be perceived by the market as an investment by a BP in NWBO’s technology and so would have a limited impact on the SP compared to a revenue generating partnership. Plus, it would essentially mean NWBO funding a trial almost alone something they could not do with Direct past the Phase 1 stage.
On paper it would be a partnership and so it’s real in that sense but fake in its benefits (from NWBO’s standpoint).
News 
Market Data 
Discover 
AI
